Tumor-associated antigen-derived peptide epitope

Tumor-associated antigen-derived peptide epitopes are short amino acid sequences generated from proteins that are overexpressed or aberrantly expressed in tumor cells. These peptides become targets for the immune system when they are processed and presented on the surface of cancer cells by major histocompatibility complex class I molecules. Recognition by cytotoxic T lymphocytes can lead to targeted destruction of tumor cells. Such epitopes can be derived from a variety of sources including mutated proteins, overexpressed normal proteins, or aberrantly spliced products unique to tumors[1][2]. They play a central role in cancer immunotherapy strategies such as therapeutic vaccines and adoptive T cell transfer. However, because this term refers broadly to any such epitope rather than a single molecular entity or receptor, it is not itself a canonical target but rather a category encompassing many possible targets with varying specificity and immunogenicity[1][2]. The entry "Tumor-associated antigen-derived peptide epitopes" is overly broad and does not refer to one specific molecule or receptor but instead describes an entire class/category of potential therapeutic targets. For structured data purposes, each individual epitope should be specified by its source protein/antigen and sequence context; otherwise this entry lacks specificity required for most databases focused on druggable targets[3].

Other names

TAA-derived peptide epitopeTumor antigen-derived peptideTumor-associated antigen (TAA) epitope

Induction of CTL-mediated killing of tumor cells via recognition of presented peptides on MHC class I molecules.